All lobbying filings

BRIDGEBIO PHARMA, INC.

BRIDGEBIO PHARMA, INC. filed a Q2 report for BRIDGEBIO PHARMA, INC. on July 20, 2026.

Lobbying for BRIDGEBIO PHARMA, INC. · Biotech company

All filings by BRIDGEBIO PHARMA, INC. · Everything BRIDGEBIO PHARMA, INC. has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Expenses

$500,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Lobbyists on this filing 1

SCOTT HINKLE New on this filing

Previously held: Sr. Leg. Assistant and Counsel, Policy Dir. and Counsel, Leg. Dir. and Counsel, Deputy Chief of Staff (CoS)/Leg. Dir./Counsel, CoS and Counsel, DC CoS and Counsel, Sr. Advisor and Counsel for Rep. Juan Vargas; CoS and Counsel for Rep. Raul Ruiz

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Pharmacy

Orphan drug policies General issues and provisions related to PBM Reform General issues and provisions related to tariffs H.R.1532 and S.822 - Scientific EXPERT Act

Bills named in this filing 2

H.R. 1532
Scientific EXPERT Act of 2025
S. 822
Scientific EXPERT Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.